Form 4: Apellis Pharmaceuticals CEO Granted Significant Stock Option Award

Apellis Pharmaceuticals, Inc. CEO and Director Cedric Francois was granted 287,500 stock options with an exercise price of $19.39, vesting over two years.

Summary

• Cedric Francois, Chief Executive Officer and Director of Apellis Pharmaceuticals, Inc. (APLS), was granted 287,500 stock options.
• The stock options have an exercise price of $19.39 per share.
• The grant date for these options was June 9, 2025.
• The options will vest over a two-year period, with 50% vesting on the one-year anniversary and the remaining 50% on the two-year anniversary of the grant date.
• Vesting is contingent upon Cedric Francois's continued service to the company.
• The options have an expiration date of June 9, 2035.
• The filing was made on June 11, 2025, by David Watson, attorney-in-fact for Cedric Francois.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates continued commitment and alignment of a key executive with shareholder interests through a standard compensation mechanism. It does not, however, provide new operational or financial performance data.

Positives

• The grant of stock options aligns the interests of the CEO, Cedric Francois, with those of the shareholders, as the value of the options is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment and continued service from a key executive.

Negatives

• No direct negatives are apparent from this routine compensation disclosure.

Risks

• The primary risk associated with this grant is that the options may not vest if Cedric Francois's service to the company ceases before the vesting dates.
• The value of the options is subject to market fluctuations of Apellis Pharmaceuticals' common stock; if the stock price does not exceed the exercise price, the options may not be 'in the money'.

Future Outlook

The vesting schedule of the stock options indicates an expectation of continued service from the Chief Executive Officer for at least the next two years, reinforcing management stability.

Management Comments

• While no direct quotes are provided, the grant of stock options to Cedric Francois, as CEO, reflects a standard executive compensation practice aimed at incentivizing long-term performance and retention.

Industry Context

The granting of stock options to key executives like the CEO is a common practice in the biotechnology and pharmaceutical industries, serving as a significant component of executive compensation packages designed to align management incentives with shareholder value creation. This is a routine disclosure for executive equity awards.

Comparison to Industry Standards

• The structure of this stock option grant, including a multi-year vesting schedule, is consistent with typical executive compensation practices observed across publicly traded companies, particularly within the life sciences sector.
• The exercise price being set at the market price on the grant date (assuming $19.39 was the market price) is standard for incentive stock options.

Corporate Governance

Related Party Transactions

• This filing details an equity award to Cedric Francois, the Chief Executive Officer and a Director of Apellis Pharmaceuticals, Inc., which is a transaction between the company and a key insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the CEO's financial interests with shareholder value creation, potentially leading to more focused long-term growth strategies.
• Employees: While not directly impacting all employees, executive compensation practices can influence overall company culture and compensation philosophy.

Next Steps

• The stock options will vest in two tranches: 50% on June 9, 2026, and 50% on June 9, 2027, contingent on continued service.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, stock options, executive compensation, insider transaction, Form 4, Cedric Francois, equity award